Abstract
Currently, airborne transmission is seen as the most important transmission path for SARS-CoV-2. In this investigation, models of other researchers with the aim to predict an infection risk for exposed persons in a room through aerosols emitted by an infectious case-patient were extended. As a novelty – usually neglected – parameters or boundary conditions, namely the non-stationarity of aerosol and the half life of aerosolized virus, were included and a new method for determining the quanta emission rate based on measurements of the particle emission rate and respiratory rate at different types of activities was implemented. As a second step, the model was applied to twelve outbreaks to compare the predicted infection risk with the observed attack rate. To estimate a “credible interval” of the predicted infection risk the quanta emission rate, the respiratory rate as well as the air volume flow were varied.
In nine out of twelve outbreaks, the calculated predicted infection risk via aerosols was found to be in the range the attack rate (with the variation of the boundary conditions) and reasons for the observed larger divergence were discussed.
The validation was considered successful and therefore, the use of the model could be recommended to predict the risk of an infection via aerosols in given situations. Furthermore, appropriate preventive measures can be designed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding has been received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethical committee approval necessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
all data presented in the manuscript
